Analyse

Analyst Huh Hyemin of Kiwoom Securities forecasts Jongkundang's Q2 sales at 4.629 trillion KRW, up 8% YoY, but operating profit at 193 billion KRW, 13% lower, slightly below consensus.

A discount program for OTC oral contraceptives requires pharmacies to buy 210+ units for the lowest price, a threshold many small pharmacies find unattainable, sparking controversy.

Yuhan Corp. reports its drug segment reached 1.4 trillion KRW in 2025, a 3.5% YoY increase, driven by balanced growth of prescription and OTC products.

A survey of Korean 20‑year‑olds shows they buy vitamins at health‑beauty stores like Olive Young and turn to pharmacies only for illness‑related medicines.

Following MFDS removal of pediatric use for diacetyl hexyl smectite, demand shifted to HydraSec, causing shortages; Samjin Pharma expects supply normalization this week.

Compounding volumes held steady while OTC sales slipped slightly in Korea's week 27, with modest drops across cough, throat, pain and digestive product lines.

Pamgen Science introduced ‘VitainB’, Korea’s first sustained‑release vitamin B complex, targeting the high‑dose vitamin market.

Six biotech firms from Chungcheongbuk-do, supported by KBIOHealth, reported $40.59 million in export discussions and $1 million in investment talks at BIO USA 2026 in San Diego.

Taejeon Group has signed an exclusive distribution agreement with US health‑supplement brand Metagenics, aiming to launch its products to Korean pharmacists, healthcare professionals and consumers.

Following the shutdown of Erwinase’s manufacturer, Korea’s Rare & Essential Medicines Center signed a contract for Enrylaze, restoring treatment continuity for acute lymphoblastic leukemia and lymphoma patients.